OH-PARKER-AEROSPACE
24.4.2024 16:01:32 CEST | Business Wire | Press release
Parker Aerospace, a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, will participate in the HyFIVE consortium of industry and academic partners developing a world-leading liquid hydrogen fuel system and supply chain supporting zero-emission aviation in the 2030s.
In addition to Parker Aerospace, HyFIVE includes fellow industry partners Marshall and GKN Aerospace, as well as academic partners University of Manchester, University of Bath and Cardiff University. The project is supported by the ATI Programme, a partnership between the UK’s Department for Business and Trade, the Aerospace Technology Institute (ATI) and Innovate UK (UKRI). The consortium will receive initial funding of £17 million ($21.5 million) from industry, matched by £20 million ($25 million) from the UK Government.
A path to zero emissions flight
The objective of the HyFIVE consortium is to develop, test and validate a modular and scalable cryogenic hydrogen fuel system architecture appropriate for multiple types of aircraft, and support of hydrogen electric propulsion or hydrogen combustion powertrains. The initiative will address technology development for hydrogen fuel systems in five key areas: storage, conveyance, indication, fueling and venting.
Collaboration among industry leaders
Parker Aerospace, which includes Parker Meggitt, has a broad spectrum of solutions for both airframes and engines and will furnish its advanced technology and expertise in the areas of sensing, thermal management and fluid conveyance.
Marshall will be leading the HyFIVE efforts, providing its expertise in complex system design, integration and certification, honed over decades of delivering aircraft fuel systems and complex aircraft modification projects.
GKN Aerospace, specializing in the design, manufacture and assembly of aircraft structures, engine components and systems, will contribute its industry-leading advanced materials and hydrogen cryogenic system optimization expertise.
Academic partners University of Manchester, University of Bath and Cardiff University have been selected for their world-leading research capabilities and advanced testing facilities in the areas of hydrogen-electric propulsion, cryogenic applications, power transmission, turbomachinery and next-generation material development.
Technical program detailed
The HyFIVE consortium members have defined a full technical program spanning several years, from initial architecture development and supplier engagement to ground testing and final design review for the integrated fuel system.
By 2027, the consortium plans to:
- Develop and validate an integrated family of mature fuel system technologies and capabilities conducive to certification.
- Conduct ground demonstration of an integrated fuel system encompassing the storage, conveyance, indication, venting and fueling systems.
- Open a range of flight demonstration and exploitation paths with prospective customers.
- Develop a customer-ready supply chain and industrialization strategy.
The timely achievement of these objectives will support the successful introduction of a new generation of zero-emissions aircraft in the 2030s.
"Parker is fully committed to sustainability, which is why we are making focused investments in innovative, next-generation technologies,” said Tracy Rice, vice president of technology and innovation for Parker Aerospace. “Hydrogen fuel systems play a critical role in achieving zero emissions in aviation and working with our partners on this project will enable us to further advance our expertise in this area and drive the development of innovative solutions that support a more sustainable future.”
About Parker Aerospace. At Parker Aerospace, we develop technologies and innovative solutions that enable reliable, efficient and increasingly sustainable flight for the lifecycle of the aircraft, including aftermarket support. Parker stands at the forefront of aviation technology with an expanded range of products and services that sits nose-to-tail across the entire aircraft. Our passionate people with deep engineering expertise, together with our breadth of differentiated technologies, ensure that we make the extraordinary happen and continue to shape the future of aviation in partnership with our customers.
About Parker Hannifin. Parker is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Learn more at www.parker.com or @parkerhannifin.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424285169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom